These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34380592)

  • 1. Trends and variations in utilization and costs of radiotherapy for prostate cancer: A SEER medicare analysis from 2007 through 2016.
    Mukherjee K; Small W; Duszak R
    Brachytherapy; 2022; 21(1):12-21. PubMed ID: 34380592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.
    Halpern JA; Sedrakyan A; Hsu WC; Mao J; Daskivich TJ; Nguyen PL; Golden EB; Kang J; Hu JC
    Cancer; 2016 Aug; 122(16):2496-504. PubMed ID: 27224858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost implications of the rapid adoption of newer technologies for treating prostate cancer.
    Nguyen PL; Gu X; Lipsitz SR; Choueiri TK; Choi WW; Lei Y; Hoffman KE; Hu JC
    J Clin Oncol; 2011 Apr; 29(12):1517-24. PubMed ID: 21402604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.
    Jacobs BL; Yabes JG; Lopa SH; Heron DE; Chang CH; Schroeck FR; Bekelman JE; Kahn JM; Nelson JB; Barnato AE
    Cancer; 2017 Aug; 123(15):2945-2954. PubMed ID: 28301689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
    Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
    JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The adoption of new adjuvant radiation therapy modalities among Medicare beneficiaries with breast cancer: clinical correlates and cost implications.
    Roberts KB; Soulos PR; Herrin J; Yu JB; Long JB; Dostaler E; Gross CP
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1186-92. PubMed ID: 23182396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-driven activity-based cost comparison of prostate cancer brachytherapy and intensity-modulated radiation therapy.
    Dutta SW; Bauer-Nilsen K; Sanders JC; Trifiletti DM; Libby B; Lash DH; Lain M; Christodoulou D; Hodge C; Showalter TN
    Brachytherapy; 2018; 17(3):556-563. PubMed ID: 29519605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancer.
    Vu CC; Blas KG; Lanni TB; Gustafson GS; Krauss DJ
    Brachytherapy; 2018; 17(6):852-857. PubMed ID: 30076108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity modulated radiation therapy following lumpectomy in early-stage breast cancer: Patterns of use and cost consequences among Medicare beneficiaries.
    Halasz LM; Patel SA; McDougall JA; Fedorenko C; Sun Q; Goulart BHL; Roth JA
    PLoS One; 2019; 14(9):e0222904. PubMed ID: 31568536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.
    Satkunasivam R; Kim AE; Desai M; Nguyen MM; Quinn DI; Ballas L; Lewinger JP; Stern MC; Hamilton AS; Aron M; Gill IS
    J Urol; 2015 Aug; 194(2):378-85. PubMed ID: 25711194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
    Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
    Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost of cancer management by stage at diagnosis among Medicare beneficiaries.
    Reddy SR; Broder MS; Chang E; Paydar C; Chung KC; Kansal AR
    Curr Med Res Opin; 2022 Aug; 38(8):1285-1294. PubMed ID: 35285354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity.
    Yu JB; Soulos PR; Herrin J; Cramer LD; Potosky AL; Roberts KB; Gross CP
    J Natl Cancer Inst; 2013 Jan; 105(1):25-32. PubMed ID: 23243199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of trends in the cost of initial cancer treatment.
    Warren JL; Yabroff KR; Meekins A; Topor M; Lamont EB; Brown ML
    J Natl Cancer Inst; 2008 Jun; 100(12):888-97. PubMed ID: 18544740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
    Muralidhar V; Mahal BA; Butler S; Lamba N; Yang DD; Leeman J; D'Amico AV; Nguyen PL; Trinh QD; Orio PF; King MT
    J Urol; 2019 Nov; 202(5):973-978. PubMed ID: 31144590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of Intensity-modulated Radiation Therapy for Older Patients with Stage III Lung Cancer.
    Kale MS; Mhango G; Bonomi M; Federman A; Sigel K; Rosenzweig KE; Wisnivesky JP
    Ann Am Thorac Soc; 2016 Sep; 13(9):1593-9. PubMed ID: 27299697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Projections of the cost of cancer care in the United States: 2010-2020.
    Mariotto AB; Yabroff KR; Shao Y; Feuer EJ; Brown ML
    J Natl Cancer Inst; 2011 Jan; 103(2):117-28. PubMed ID: 21228314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of race/ethnicity and patient care experiences with healthcare utilization and healthcare costs among prostate cancer survivors: A SEER-CAHPS study.
    Pandit AA; Halpern MT; Gressler LE; Kamel M; Payakachat N; Li C
    J Geriatr Oncol; 2024 Apr; 15(3):101748. PubMed ID: 38493533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National Utilization, Survival, and Costs Analysis of Treatment Options for Stage I Non-Small Cell Lung Cancer: A SEER-Medicare Database Analysis.
    Mukherjee K; Davisson N; Malik S; Duszak R; Kokabi N
    Acad Radiol; 2022 Feb; 29 Suppl 2():S173-S180. PubMed ID: 34404607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cost of Metastatic Prostate Cancer in the United States.
    Olsen TA; Filson CP; Richards TB; Ekwueme DU; Howard DH
    Urol Pract; 2023 Jan; 10(1):41-47. PubMed ID: 37103444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.